Home

William J Sharbaugh

CIK 1399883 · Chief Operating Officer · last filed 2026-06-12

William J Sharbaugh is a Chief Operating Officer who has filed 24 SEC Form 4 insider transactions across 3 companies since 2007. The most recent filing, for FTRE, was dated Jun 12, 2026. Across all open-market trades the lifetime net is +$810.0K, making them a net buyer over the disclosed history. 20 SEC filings were submitted jointly with PHARMACEUTICAL PRODUCT DEVELOPMENT INC.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$0

Companies

3

Total Filings

24

Lifetime Open-Market Net

$810.0K

Filer Profile

Reported Address
C/O PHARMACEUTICAL PRODUCT DEVELOPMENT
929 NORTH FRONT STREET
WILMINGTON, NC 28401
Related Filers
PHARMACEUTICAL PRODUCT DEVELOPMENT INC — 20 joint filings, latest 2011-12-06
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses. View filings on SEC EDGAR.

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
FTRE Director — $17.20 — $0 2 2026-06-12
PPD, Inc. (PPD) Delisted Chief Operating Officer 0 $47.28 $0 $810.0K 4 2021-12-08
PHARMACEUTICAL PRODUCT DEVELOPMENT INC (PPDI) Delisted Chief Operating Officer 13,906 — — $0 18 2011-12-06

Recent Filings

24 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2026-06-12 FTRE Grant (A) — $0 EDGAR
2025-11-24 FTRE Grant (A) — $0 EDGAR
2021-12-08 PPD, Inc. (PPD) Delisted Mixed −452,485 -$21.49M EDGAR
2021-02-16 PPD, Inc. (PPD) Delisted Grant (A) — $0 EDGAR
2020-02-21 PPD, Inc. (PPD) Delisted Grant (A) — $0 EDGAR
2020-02-12 PPD, Inc. (PPD) Delisted Mixed +30,000 $810.0K EDGAR
2011-12-06 PHARMACEUTICAL PRODUCT DEVELOPMENT INC (PPDI) Delisted Mixed −13,582 -$454.3K EDGAR
2011-07-06 PHARMACEUTICAL PRODUCT DEVELOPMENT INC (PPDI) Delisted Disc (I) +589 $14.2K EDGAR
2011-02-25 PHARMACEUTICAL PRODUCT DEVELOPMENT INC (PPDI) Delisted Grant (A) — $0 EDGAR
2011-01-04 PHARMACEUTICAL PRODUCT DEVELOPMENT INC (PPDI) Delisted Disc (I) +411 $9.1K EDGAR
Showing 1–10 of 24
Page 1 of 3
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.